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Abstract. We determined the concentration of nitric oxide metabolites (NO2−+NO3−), expressed as NOx, in several clinical6
conditions. Regarding this, we have examined 25 subjects with arterial hypertension, 41 subjects with chronic kidney disease in7
conservative treatment, 106 subjects with metabolic syndrome subdivided according to the presence (n = 43) or not (n = 63) of8
diabetes mellitus, 48 subjects with obstructive sleep apnea syndrome (OSAS), 14 women with systemic sclerosis complicated9
with Raynaud’s phenomenon, 42 dialyzed subjects and 105 young subjects with acute myocardial infarction (AMI). In subjects10
with arterial hypertension, chronic kidney disease, metabolic syndrome, systemic sclerosis, as well as, in dialyzed and AMI11
subjects, we found at baseline a NOx increase. In dyalized subjects after a standard dialysis session, we observed a decrease in12
NOx. The increase in NOx in juvenile AMI was significantly influenced by cigarette smoking and less by cardiovascular risk13
factors and the extent of coronary lesions; at 3 and 12 months later than the initial event, we observed a decrease of NOx that14
remains significantly higher than the control group. In subjects with OSAS no difference in NOx was noted in comparison with15
normal controls, although their subdivision according to the apnea/hypopnea index operates a clear distinction regarding NOx16
concentration.17
Keywords:18
1. Introduction18
Even if, at baseline, the main origin of plasma nitric oxide (NO) seems to be related to endothelial19
nitric oxide synthase (eNOS), in several clinical conditions the inducible NOS (iNOS) is hyperactivated20
and this event is especially associated with the increase of cytokines such as TNF, IL-1 and interferon21
[29, 56, 75]. As it is known NO is produced through the oxidation of L-arginine in different cells by a22
family of enzymes, the nitric oxide synthases, subdivided in three major classes: neuronal-NOS (nNOS,23
type 1), inducible-NOS (iNOS, type II) and endothelial-NOS (eNOS, type III). Each isoform is encoded24
on a different chromosome: the nNOS is encoded on chromosome 12, the iNOS on chromosome 17 while25
the eNOS on chromosome 7. The biological activity of each isoform depends on different conditions,26
in fact the synthesis and activity of eNOS and nNOS requires calcium and calmodulin while the iNOS27
activity is decreased by glucocorticoids and increased by proinflammatory cytokines. The activation of28
iNOS generates NO in the measure of up 1000-fold greater than nNOS or eNOS [57] it has also been29
demonstrated that the more important modulators of these proinflammatory cytokines are the mitogen30
activated protein kinases [32]. This accelerated NO synthesis has however an opposite effect because31
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NO interacts with the superoxide anion (O2−) to produce peroxynitrite and other oxidants involved in32
tissue injury. Considering this pathophysiological aspect, NOS inhibitors have been administrated in some33
critical conditions, such as congestive heart failure [64], refractory cardiogenic shock [21], cardiogenic34
shock complicating an acute myocardial infarction [26, 58, 70] and septic shock [44]. Among the NOS35
inhibitors, the L-monomethylarginine (L-NMM), a non-selective NOS inhibitor, has been investigated36
the most. The TRIUMPH study [70] has been conducted in 130 centers and in 8 countries in North37
America and Europe, enrolling 398 patients with acute myocardial infarction (AMI) and cardiogenic38
shock; it has demonstrated, however, that the use of tilarginine acetate has no effect on mortality of39
these patients. Other authors [65] have consequently suggested avoiding further trials with non-selective40
inhibitors of NOS in the cardiovascular area. Whereas the considerations about the possible coming of41
NO are interesting. As it is known, NO metabolites, such as nitrite (NO2−) and nitrate (NO3−), usually42
evaluated together and expressed as NOx, may play a positive role in stable clinical conditions, because43
they can be reduced to NO once again [20, 49, 53, 54]. All the NO produced, including those generated44
by red blood cells subjected to several stimuli, such as mechanical and shear stress [71–73], act on the45
cardiovascular system contributing to the modulation of blood flow and vascular tone and regulating46
vascular relaxation without, however, recognizing the pivotal role played in this microcirculatory area by47
the haemorheological pattern [28, 33].48
Considering these information, we examined the behavior of NOx in different clinical conditions, such49
as arterial hypertension, chronic kidney disease (CKD) on conservative treatment, metabolic syndrome,50
obstructive sleep apnea syndrome (OSAS), systemic sclerosis, CKD in dialysis treatment and jouvenile51
acute myocardial infarction.52
2. Subjects53
We examined 7 groups of subjects.54
– The first group included 25 subjects (19 men and 6 women; mean age 44.4 ± 7.7 yrs) with55
untreated mild essential hypertension. In this group hypertension duration was of 19.3 ± 32.856
months, fasting blood glucose was 91.4 ± 10.9 mg/dl, cholesterol level was 210.0 ± 37.0 mg/dl,57
HDL-chol was 44.41 ± 8.19 mg/dl, triglycerides were 101.1 ± 7.8 mg/dl, and serum uric acid was58
5.74 ± 1.63 mg/dl. In hypertensives the body mass index (BMI) was 26.6 ± 3.5 and the waist to59
hip ratio (WHR) was 0.91 ± 0.05, while day-time systolic (S) and diastolic (D) blood pressure (BP)60
were respectively 133.80 ± 8.12 and 86.05 ± 6.79 mmHg, night-time SBP and DBP were respectively61
120.40 ± 10.86 and 75.00 ± 7.65 mmHg and the 24-h SBP and DBP were respectively 128.00 ± 8.5062
and 81.73 ± 6.36 mmHg. This group was compared with a control group including 27 healthy subjects63
(20 men and 7 momen; mea age 41.3 ± 6.2 yrs).64
– The second group included 41 subjects (25 men and 16 women; mean age 64.7 ± 11.1 yrs) with65
clinically stable CKD on conservative management. The causes of CKD were chronic pyelonephritis66
in 9 subjects, nephroangiosclerosis in 6, chronic pyelonephritis associated with nephroangiosclerosis67
in 8, chronic glomerulonephritis in 5, diabetic nephropathy in 8 and polycystic kidney disease in 5. In68
this group serum creatinine was 3.05 ± 1.79 mg/dl, creatinine clearance was 28.56 ± 17.13 ml/min,69
haemoglobin level was 12.2 ± 2.1 g/dl. The CKD subjects were subdivided according to age in two70
subgroups: 22 subjects <65 yrs and 19 subjects ≥65 yrs. This group was compared with a control71
group including 51 healthy subjects (39 men and 12 momen; age range 24–60 yrs).
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– The third group included 106 subjects (61 men and 45 women; mean age 53.5 ± 8.9 yrs) with72
metabolic syndrome (MS) defined according the International Diabetes Federation (IDF) criteria [3].73
In this group BMI was 32.32 ± 4.53, waist circumference was 106.7 ± 11.2 cm, SBP and DBP were74
respectively 132.1 ± 16.3 and 81.2 ± 99 mmHg, fasting blood glucose was 114.3 ± 44.3 mg/dl, HDL-75
chol was 40.4 ± 10.8 mg/dl and triglycerides were 220.2 ± 147.8 mg/dl. This group was compared76
with a control group including 54 healthy subjects (35 men and 19 momen; mean age 41.3 ± 7.4 yrs)77
recruited from the hospital staff.78
– The fourth group included 48 subjects (36 men and 12 women; mean age 50.3 ± 14.68 yrs) with79
OSAS. In this group BMI was 35.46 ± 7.28, waist circumference was 118.75 ± 15.88 cm, neck80
circumference was 44.4 ± 4.77 cm, and the apnea/hypopnea index (AHI) was 38.47 ± 25.39. OSAS81
subjects were subdivided according to the AHI value in two subgroups: Low (21 subjects with AHI82
<30) and High (27 subjects with AHI >30). This group was compared with a control group including83
54 healthy subjects (35 men and 19 momen; mean age 41.3 ± 7.4 yrs) recruited from the hospital staff.84
– The fifth group included 14 women (mean age 45.4 ± 5.4 yrs) with systemic sclerosis complicated85
with Raynaud phenomenon. In these patients the duration of the disease was 3.1 ± 2.0 yrs; each86
patient showed skin disease, 3 subjects had esophageal disease, 2 subjects had pulmonary alterations87
and 1 subject showed renal damage. Immunological alterations (ANA, anti-Scl, anti SSA) were88
demonstrated in 12 women. This group was compared with a control group including 12 healthy89
women (mean age 35.1 ± 6.5 yrs).90
– The sixth group included 42 dialyzed subjects (21 men and 21 women; mean age 66.83 ± 14.891
yrs). The cause of CKD was unknown in 12 subjects, nephroangiosclerosis was demonstrated in92
12, chronic glomerulonephritis in 4, diabetic nephropathy in 10 and polycystic kidney disease in93
4. Dialysis vintage in the whole group was 55.3 ± 43.5 months. In this group the behavior of NOx94
was evaluated before and after a standard hemodialysis session. This group was compared with a95
control group including 51 healthy subjects (39 men and 12 momen; age range 24–60 yrs).96
– The seventh group included 105 young subjects (97 men and 8 women, aged <46 yrs) with recent97
AMI. The mean age was 39.6 ± 5.5 yrs. The time interval between AMI onset and the evaluation98
of NOx was 13.0 ± 7.0 days. AMI subje ts were subdivided according to the number of risk99
factors (family history of coronary artery diseases, smoke, hypercholesterolemia, diabetes mellitus,100
essential hypertension) into 3 subgroups: 38 subjects had 0 to 1 risk factor, 35 had 2 risk factors and101
32 had 3 to 5 risk factors. On the basis of coronary angiography (performed only in 92 subjects),102
AMI subjects were subdivided into 3 subgroups considering the extent of coronary lesions: 21103
subjects showed no significant lesions, 1-vessel disease was present in 41 subjects and 2- or 3-vessel104
disease was observed in 30 subjects. This group was compared with a control group including 51105
healthy subjects (39 men and 12 momen; age range 24–60 yrs).106
3. Methods107
On fasting venous blood the NO production was evaluated by a micromethod which measures the108
concentration of NO metabolites: nitrite and nitrate (NOx). In vivo NO has a very short life (less than109
0.1 sec) and it is converted into nitrite (NO2−), which has a half-life of few minutes, and into the more110
stable nitrate (NO3−). Then NOx represents almost only the nitrate concentration. In the laboratory111
method adopted by us at first nitrate was converted into nitrite by a nitrate reductase and then nitrite was112
assessed by spectrophotometry after addition of Griess reagent.
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4. Statistical analysis113
Data were expressed as means ± S.D.; the difference between normal subjects (N) and each group of114
patients was evaluated according to the Student’s t test for unpaired data. The statistical difference between115
control subjects and subjects with MS subdivided according to the presence or not of diabetes mellitus116
was estimated according to the 1-way analysis of variance (ANOVA) integrated with the Bonferroni test.117
Same statistical approach was used for the examination of OSAS subjects subdivided according to the118
AHI value and for the examination of AMI subjects, subdivided according to risk factors and extension119
of coronary lesions. The evaluation of NOx before and after dialysis was effected using the Student’s120
t test for paired data; same approach was employed to evaluate NOx before and after treatment with121
intravenous iloprost in subjects with systemic sclerosis and to evaluate NOx at the initial stage of AMI122
and 3 and 12 months later. The correlations were performed employing the linear regression test. The123
null hypothesis was rejected for p values <0.05.124
5. Results125
The obtained data are described for each clinical condition.126
5.1. Arterial hypertension127
In this group of subjects with mild essential hypertension (EH) we observed [15] a significant increase128
in NOx (N = 28.36 ± 18.36; EH = 48.78 ± 23.17, p < 0.001). The NOx was not related to metabolic param-129
eters (fasting glucose level, lipid pattern, uric acid, urea, creatinine), to BMI and WHR or to the blood130
pressure values (day-time, night-time and 24-h systolic and diastolic blood pressure).131
5.2. Chronic kidney disease132
In this group of CKD on conservative treatment we found [12] a significant rise in NOx133
(N = 24.38 ± 15.67; CKD = 74.19 ± 69.05, p < 0.001). In this group no correlation was noted between134
NOx, creatinine level and creatinine clearance. The subdivision of these subjects according to age did135
not show any difference (data not shown).136
5.3. Metabolic syndrome137
In this group of subjects with MS, we observed [13] a significant increment in NOx (N = 28.07 ± 18.83;138
MS = 79.82 ± 29.22, p < 0.001). This finding was also present between normal subjects and MS subjects139
with diabetes mellitus (N = 28.07 ± 18.83; DMS = 78.10 ± 20.76, p < 0.001) and between normal sub-140
jects and MS subjects without diabetes mellitus (N = 28.07 ± 18.83; NDMS = 80.99 ± 33.93, p < 0.001).141
Testing the linear regression between NOx, age, anthropometric profile, blood pressure values and gly-142
cometabolic pattern, we found a positive correlation between NOx and triglycerides (r = 0.344, p < 0.001)143
in the whole group of MS subjects, a positive correlation between NOx and total cholesterol (r = 0.442,144
p < 0.01) and between NOx and LDL-cholesterol (r = 0.441, p < 0.01) in the subgroup of diabetic subjects145
(N = 43), and a positive correlation between NOx and triglycerides (r = 0.43, p < 0.001) while a negative146
correlation between NOx and HDL-cholesterol (r = −0.287, p < 0.05) in the subgroup of nondiabetic147
subjects (N = 63).
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5.4. OSAS148
In this group of subjects no statistical difference in NOx was observed in comparison with normal149
controls (N = 28.07 ± 18.83; OSAS = 27.49 ± 10.13). However, subdividing the whole group of OSAS150
according to AHI value in two subgroups (Low: AHI <30, High: AHI >30), we noted a slight decrease of151
NOx in the subgroup with AHI >30 in comparison with the subgroup with AHI <30 (H = 22.84 ± 7.64;152
L = 33.47 ± 10.05, p < 0.05), but not with normal controls. We found a negative correlation between NOx153
and AHI in the whole group of OSAS subjects (r = −0.615, p < 0.001), in the subgroup with low AHI154
(r = −0.490, p < 0.05) and also in the subgroup with high AHI (r = −0.413, p < 0.05).155
5.5. Systemic sclerosis156
In this group of subjects with systemic sclerosis (SS) complicated by Raynaud phenomenon, we157
observed [47] a slight increase in NOx (N = 23.26 ± 16.11; SS = 37.77 ± 18.46, p < 0.05). After a short158
treatment with intravenous iloprost (0.5 to 2 ng/kg/min, 6 hours/die for 5 consecutive days and, after an159
interval of 2 days, for another 5 consecutive days) we noted a marked increase in NOx concentration160
(before iloprost = 37.77 ± 18.46; after iloprost = 61.19 ± 28.79, p < 0.05).161
5.6. Dialyzed subjects162
In this group of dialyzed subjects (DS) we found [11, 45] a significant increase in NOx (N = 24.38 ± 15;163
DS = 69.20 ± 35.33, p < 0.001). The subdivision of DS according to dialysis vintage did not show any164
difference in NOx concentration (data not shown). The trend of NOx before and after a standard165
hemodialysis session showed instead a significant decrease of this parameter (before = 69.20 ± 35.33;166
after = 26.80 ± 17.80, p < 0.001). During the dialysis session, the employment of different filters did not167
influence the NOx behavior (data not shown).168
5.7. Acute myocardial infarction169
In this group of young subjects with AMI we found [46] a significant increase in NOx170
(N = 24.38 ± 15.67; AMI = 64.47 ± 31.90, p < 0.001). Subdividing AMI subjects into smokers and171
nonsmokers, we noted that NOx was significantly lower in nonsmokers (smokers = 70.91 ± 33.38; non-172
smokers = 50.85 ± 15.31, p < 0.05). Subdividing AMI subjects according to the number of risk factors or173
of stenosed coronary vessels, no significant difference in NOx concentration between the subgroups was174
observed. In 55 AMI subjects NOx was evaluated at the initial stage and after 12 months and it showed175
a significant decrease (initial stage = 69.33 ± 27.38; 12 months = 37.71 ± 17.29, p < 0.001). In a small176
group of AMI subjects (38 men and 5 women) we evaluated [14] the trend of NOx at the initial stage177
(T1), after 3 months (T2) and after 12 months (T3) observing its progressive decrease (T1 = 70.14 ± 26.70,178
T2 = 56.70 ± 23.87, T3 = 37.27 ± 18.96).179
6. Conclusive consideration180
Our finding on mild essential hypertension points out a significant NOx increase. As in this clinical181
condition several inflammatory molecules seem to be released, this datum might be related to a NO182
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overproduction by macrophages through iNOS activation. However, it must be underlined that this finding,183
that is in agreement with those of few authors [60, 79], conflicts with the observations of others [6, 38,184
39, 74]. Considering this latter remark, it is not possible to exclude, as far as the NOx concentration is185
concerned, the role played in this cardiovascular disease by impaired microvascular function, that can186
later progress into capillary rarefaction, as has been clearly demonstrated previously by several studies187
[19, 22, 27, 37]. This microvascular alteration perhaps is not present in subjects with mild essential188
hypertension.189
The findings observed in CKD on conservative treatment and in dialyzed subjects need to be examined190
together. In these two groups, in fact, the increase in NOx, described also by other authors [36], may be191
explained by impairment of renal excretion [50] or by macrophage NO synthesis. This latter hypothesis192
deserves to be underlined considering the role played by asymmetric dimethylarginine (ADMA) in CKD193
[10]. As it is known, in fact, ADMA removal is blocked in CKD subjects leading to high plasma levels194
of this inhibitor of all NOS isoforms [48]. Regarding the trend of NOx before and after dialysis session,195
we observed a significant decrease in NOx after dialysis as did other authors [78], although Zhang et196
al. have found a NOx increase [80]. This discrepancy regarding the trend of NOx after dialysis must be197
further developed.198
In MS subjects a NOx increase was observed and this finding was similar in the two subgroups of199
diabetic and nondiabetic subjects. These data agree with the observations of othes who studied NOx in200
MS or in its components [7, 8, 15, 17, 35, 36, 60, 62, 63, 79]. Our results show in diabetic MS subjects201
a positive correlation between NOx and total cholesterol and LDL-cholesterol while in nondiabetic202
subjects a negative correlation between NOx and HDL-cholesterol. The literary data do not confirm203
these findings in healthy adult subjects [31] or in overweight and obese women [59] while in adolescents204
NOx has been correlated positively to the total cholesterol and LDL-cholesterol and negatively to HDL-205
cholesterol [18]. We observed a positive correlation between NOx and triglycerides in the entire group206
of MS subjects and in the subgroup of nondiabetics. This datum, in agreement with those described by207
others in postmenopausal MS women [16], in adolescents [18] and in a general healthy population [31],208
is different from that observed [24] in subjects with normal-weight obese syndrome.209
The behavior of NOx in subjects with OSAS is interesting. This is confirmed by some authors [23], but210
conflicts with other papers [40, 66]; the subdivision of these subjects according to AHI shows a marked211
decrease in NOx in the subgroup with AHI >30. Agreeing with other authors [30], in the entire group212
and in the two subgroups of OSAS we found a negative correlation between NOx and AHI. Another213
interesting finding is the positive correlation between AHI and neck circumference observed in entire214
group (r = 0.60, p < 0.001) and in the subgroup with AHI <30 (r = 0.55, p < 0.05). Later we will examine,215
especially in OSAS subjects with AHI >30, the trend of NOx after treatment with continuous positive216
airway pressure (cPAP); some papers have in fact described a NOx increase after therapy with cPAP [40,217
61, 66], differently from others [23].218
In subjects with systemic sclerosis complicated by Raynaud’s phenomenon we observed a NOx increase219
and this datum is entirely in agreement with those of some authors [25, 55, 69, 77] but partially with220
those of others who described only a nitrite (NO2−) increase [61] or a nitrate increase (NO3−) [5]. Other221
authors [4, 52] however, found a NOx decrease in this clinical condition. In the paper of Takagi et al222
[69] NOx level was positively correlated with some clinical features, such as the extent of skin fibrosis,223
short disease duration and active fibrosing alveolitis. In a subgroup of subjects with systemic sclerosis224
examined by Mok et al [55] a positive correlation between NOx and pulmonary arterial pressure was225
found and prednisolone treatment was associated with decreased NOx. In our small group of subjects226
with systemic sclerosis the venous infusion of iloprost increases significantly the value of NOx. This227
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finding is different from that observed by others [51] in 29 subjects with chronic peripheral ischaemia (15228
suffering from systemic sclerosis); in this group in fact iloprost infusion enhances microvascular function229
with clinical benefits but without any NOx variation.230
In young subjects with AMI we found a marked increase in NOx, in agreement with other authors [68]. As231
it is known, during the acute phase of AMI, iNOS activity increases as a reaction to the high oxidative stress232
[76]. In experimental models the ligation of the left anterior descending coronary artery was associated233
with NOx increase, which reached a peak after 3 days [2]. The same behavior of NOx has been observed234
in a small group of subjects with anterior myocardial infarction examined at 24, 48 and 72 hours after the235
event [1]. In this research the NOx peak occurred 2 or 3 days after the onset of symptoms, suggesting that236
NOx increase was correlated with iNOS activation induced especially by cytokines. In our study [14, 46]237
NOx was significantly reduced in nonsmokers and that its trend was conditioned more by cardiovascular238
risk factors than by the extent of coronary lesions. At 3 and 12 months we observed a progressive decrease239
of NOx, remaining at both times significantly higher than the control group. The persistent increase in240
NOx could be a further confirmation of a chronic inflammatory state, that might be related to the genetic241
profile of these subjects, showing in many cases pro-inflammatory alleles [9, 34, 41–43].242
In conclusion, the data described seem to point out a role of iNOS activation in almost all the clinical243
conditions considered. The iNOS activity is stimulated in particular by pro-inflammatory cytokines and244
by oxidative stress, which is evident in each group of patients studied by us as increased lipid peroxidation245
and protein oxidation and decreased total antioxidant status. Then it is possible to suppose that the NOx246
increase found in arterial hypertension, chronic kidney disease, metabolic syndrome, systemic sclerosis247
and juvenile myocardial infarction can reflect this hyperactivation. Whereas the behavior of NOx in OSAS248
subjects needs further investigation. Its trend, in fact, depends on OSAS severity expressed as AHI. The249
subdivision of OSAS subjects according to this index allows the discrimination of two subgroups and250
the demonstration that in the subgroup with AHI >30 the NOx value is significantly lower than in the251
subgroup with AHI <30. It is not possible to exclude that this behavior might depend, through the nocturnal252
hypoxemia, on the altered balance between NOx synthesis and NOx removal and this hypothesis seems253
to be supported by the increase in NOx value after cPAP therapy.254
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